search
Back to results

CirQPOD Shoulder Study

Primary Purpose

Hypotension on Induction

Status
Withdrawn
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
CirQPOD
Standard airway management
Sponsored by
Zoll Medical Corporation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Hypotension on Induction focused on measuring Intraoperative hypotension

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥18 years
  • American Society of Anesthesiologists (ASA) physical status class ≤3
  • Scheduled for surgery in sitting/ beach-chair positions under general anesthesia in the Cleveland Clinic main campus
  • Planned length of surgery >60 minutes

Exclusion Criteria:

  • Severe peripheral vascular disease or other contraindication for use of vasopressor infusion
  • Obstructive lung disease - moderate or severe asthma or COPD
  • Baseline hypoxemia (SpO2<92% on room air)
  • Body Mass Index (BMI) >35
  • Congestive heart failure
  • Pneumothorax or hemothorax
  • Uncontrolled hemorrhage
  • Planned intraoperative hypotension
  • Contraindication to trans-esophageal echocardiography (esophageal stricture, surgery involving the esophagus or stomach)

Sites / Locations

  • Outcomes Research, Anesthesia Institute, Cleveland Clinic

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

IPR therapy

Standard airway

Arm Description

Intrathoracic pressure regulation (IPR) therapy level of -10 cmH2O (-7 cmH2O for run-in) provided by the CirQPOD device during shoulder surgery in the sitting position

Standard airway pressure (PEEP of +5 cmH2O) during shoulder surgery in the sitting position

Outcomes

Primary Outcome Measures

Phenylephrine use
Amount of phenylephrine required to maintain MAP of 80±5 mmHg

Secondary Outcome Measures

Pulmonary artery pressure
pressure in the pulmonary artery as measured by transesophageal echocardiography (TEE)
Atelectasis
presence and amount of atelectasis as determined by chest computerized tomography (CT)
PaO2
post-operative partial arterial oxygen pressure measured by arterial blood gas (ABG)

Full Information

First Posted
March 2, 2020
Last Updated
January 25, 2022
Sponsor
Zoll Medical Corporation
Collaborators
The Cleveland Clinic
search

1. Study Identification

Unique Protocol Identification Number
NCT04299776
Brief Title
CirQPOD Shoulder Study
Official Title
A Randomized Clinical Trial on the Effects of Active Intrathoracic Pressure Regulation Therapy on Hemodynamic Stability During Shoulder Surgery in the Sitting Position
Study Type
Interventional

2. Study Status

Record Verification Date
January 2022
Overall Recruitment Status
Withdrawn
Why Stopped
Review of new pre-clinical data
Study Start Date
January 28, 2020 (Actual)
Primary Completion Date
March 28, 2020 (Actual)
Study Completion Date
March 28, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Zoll Medical Corporation
Collaborators
The Cleveland Clinic

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Intrathoracic pressure regulation (IPR) therapy, delivered by impedance threshold devices (ITDs) or intrathoracic pressure regulators (ITPRs), increases venous return, preload, cardiac output, blood pressure, and cerebral perfusion pressure by intermittently creating negative intrathoracic pressure, which improves circulation in hypotensive animals and humans. By increasing systemic pressure and cerebral perfusion as well as promoting venous return, IPR therapy potentially improves cerebral oxygenation. The lower intrathoracic pressures may also reduce pulmonary artery pressure, although there is currently little evidence one way or the other. Use of an ITPR can counteract the multifactorial intraoperative hypotension common during surgeries under general anesthesia, and reduce the need for other measures to treat such hypotension; however, they might simultaneously promote pulmonary complications. The investigators will therefore assess whether the use of intrathoracic pressure regulation in adults having shoulder surgery under general anesthesia in the sitting position reduces vasoactive medication requirements compared with routine clinical practice. Simultaneously, the investigators will assess the effect of intrathoracic pressure regulation on pulmonary circulation, cerebral oxygenation, and postoperative atelectasis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypotension on Induction
Keywords
Intraoperative hypotension

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
IPR therapy
Arm Type
Experimental
Arm Description
Intrathoracic pressure regulation (IPR) therapy level of -10 cmH2O (-7 cmH2O for run-in) provided by the CirQPOD device during shoulder surgery in the sitting position
Arm Title
Standard airway
Arm Type
Active Comparator
Arm Description
Standard airway pressure (PEEP of +5 cmH2O) during shoulder surgery in the sitting position
Intervention Type
Device
Intervention Name(s)
CirQPOD
Intervention Description
CirQPOD is connected between the wye piece on ventilator/anesthesia machine tubing and the patient's airway and generates negative intrathoracic pressure during the expiratory phase of ventilation which has been shown to improve blood flow.
Intervention Type
Device
Intervention Name(s)
Standard airway management
Intervention Description
Standard airway management during surgery (PEEP of +5 cmH2O)
Primary Outcome Measure Information:
Title
Phenylephrine use
Description
Amount of phenylephrine required to maintain MAP of 80±5 mmHg
Time Frame
from device placement to start of wound closure, a period of up to four hours
Secondary Outcome Measure Information:
Title
Pulmonary artery pressure
Description
pressure in the pulmonary artery as measured by transesophageal echocardiography (TEE)
Time Frame
at least two minutes after IPR level of -10 cmH2O has been set
Title
Atelectasis
Description
presence and amount of atelectasis as determined by chest computerized tomography (CT)
Time Frame
first day post-op
Title
PaO2
Description
post-operative partial arterial oxygen pressure measured by arterial blood gas (ABG)
Time Frame
at least 20 minutes, but not more than 2 hours, after patient is free of oxygen supplementation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥18 years American Society of Anesthesiologists (ASA) physical status class ≤3 Scheduled for surgery in sitting/ beach-chair positions under general anesthesia in the Cleveland Clinic main campus Planned length of surgery >60 minutes Exclusion Criteria: Severe peripheral vascular disease or other contraindication for use of vasopressor infusion Obstructive lung disease - moderate or severe asthma or COPD Baseline hypoxemia (SpO2<92% on room air) Body Mass Index (BMI) >35 Congestive heart failure Pneumothorax or hemothorax Uncontrolled hemorrhage Planned intraoperative hypotension Contraindication to trans-esophageal echocardiography (esophageal stricture, surgery involving the esophagus or stomach)
Facility Information:
Facility Name
Outcomes Research, Anesthesia Institute, Cleveland Clinic
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

CirQPOD Shoulder Study

We'll reach out to this number within 24 hrs